InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (206)	4/8/2002 2:31:24 PM
From: quidditch	Read Replies (2) of 508

Seems as though the Rochester Mayo Clinic hasn't found anything it likes in the anti-fibrotic drugs (a few weeks ago, someone posted a very negative interpretation from some RMC investigators who had reviewed the ITMN study of the effects of actimmune in ipf in a 19-patient trial). And since everything is to be viewed in its most negative light, since that is the ineluctible outcome of all modalities these days, should the in-licensing of perfenidone be seen as ITMN's resort to a fallback candidate for ipf because the actimmune's clinical investigators are seeing signs of non-efficacy in P3? Or (with rose colors adorning by bi-focals), should this be viewed as ITMN strengthening the franchise in the anti-fibrotics? quid

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next